GLPwatch

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of taspoglutide and exenatide in adults with type 2 diabetes whose blood sugar is not well controlled by metformin, a thiazolidinedione, or both.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 1,189 people
Who can join Ages 18–75 · all sexes
Timeline Started 2008-07 · est. completion 2011-03
Where 216 sites · Argentina, Australia, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Guatemala, Israel, Italy, Mexico, New Zealand, Peru, Puerto Rico, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Ukraine, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT00717457 ↗

Description as written by the study sponsor.

This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on study treatment is 3+ years, and the target sample size is \>500 individuals.

Treatments tested

Main thing measuredChange in HbA1c
SponsorHoffmann-La Roche
Conditions studiedDiabetes Mellitus Type 2
GLP-1 drugs exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00717457 ↗